The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
Subscribe To Our Newsletter & Stay Updated
